Cargando…
帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560986/ https://www.ncbi.nlm.nih.gov/pubmed/34628779 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25 |